SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(a)
(Amendment No. 3)
Cyclerion Therapeutics, Inc. |
(Name of Issuer)
Common Stock, no par value |
(Title of Class of Securities)
(CUSIP Number)
Peter M. Hecht
c/o Cyclerion Therapeutics, Inc.
245 First Street, 18th Floor
Cambridge, MA 02142
(857) 327-8778
Copies to:
Stanley Keller
Locke Lord LLP
111 Huntington Avenue, 9th Floor
Boston, MA 02199
(617) 239-0100 |
(Name, Address and Telephone Number
of Person Authorized to Receive Notices and Communications)
(Date of Event which Requires Filing of
this Statement)
If the filing person has previously
filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because
of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨.
Note: Schedules filed in paper
format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties
to whom copies are to be sent.
The information required on the remainder of this cover
page shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject
to the liabilities of that section of the Act by shall be subject to all other provisions of the Act (however, see the Notes).
1 |
name of reporting person
Peter M. Hecht
|
2 |
check the appropriate box if
a member of a group
(a) ¨
(b) ¨ |
3 |
sec use only |
4 |
source of funds
PF, OO
|
5 |
check box if disclosure of legal proceedings is required pursuant to items 2(d) or 2(e)
¨ |
6 |
citizenship or place of organization
United States of America
|
number of
shares
beneficially
owned
by each
reporting |
7 |
sole voting power
4,219,658
|
person with |
8 |
shared voting power
0
|
|
9 |
sole dispositive power
4,219,658
|
|
10 |
shared dispositive power
0 |
11 |
aggregate amount beneficially
owned by each reporting person
4,219,658
|
12 |
check box if the aggregate amount in row (11) excludes certain shares ¨ |
13 |
percent of class represented
by amount in row(11)
9.2%
|
14 |
type or report person
IN
|
|
|
|
|
Schedule 13D
This Amendment No. 3 (the “Amendment”) amends and supplements
the beneficial ownership statement on Schedule 13D filed with the Securities and Exchange Commission by Peter M. Hecht (the “Reporting
Person”) on May 14, 2021, as amended by Amendment No. 1 filed June 7, 2021 and Amendment No. 2 filed November 21, 2022 (the “Original
Statement”). The Original Statement, as amended by this Amendment (the “Statement”), relates to the shares of Common
Stock, no par value (the “Common Stock”) of Cyclerion Therapeutics, Inc., a Massachusetts corporation (the “Issuer”).
Capitalized terms used but not defined in this Amendment have the meanings
ascribed to them in the Original Statement. This Amendment amends the Original Statement as specifically set forth herein. Except as set
forth below, all previous Items in the Original Statement remain unchanged.
Percentages in this Amendment are based on 43,524,894 shares outstanding
as of March 19, 2023, as reported in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission for
the year ended December 31, 2022.
| Item 4. | Purpose of Transaction. |
Item
4 of the Original Statement is hereby supplemented by adding the following:
As previously reported on November 21, 2022, in Amendment No. 2 to
Schedule 13D of the Reporting Person, potential investors, including the Reporting Person, submitted a proposal to the Issuer to advance
the CNS programs, including CY6463 and CY3018, of the Issuer (the “CNS Programs”). On March 17, 2023, the Issuer received
a revised proposal regarding a potential transaction and, after consideration of that revised proposal and further discussion, on March
31, 2023, the Issuer entered into an exclusive negotiation arrangement for a limited period with a company formed by the potential investors
(“NewCo”) regarding a potential contribution by the Issuer to Newco of the CNS Programs (the “Proposed Transaction”).
Newco would be capitalized with a $70 million equity commitment by an investor syndicate that will include the Reporting Person and other
investors experienced in biotech investing. At the same time, the Reporting Person committed to make an equity investment in the Issuer,
contingent upon the execution of a definitive agreement for the Proposed Transaction, of $5 million in common stock or nonvoting convertible
preferred stock of the Issuer, the purchase price, consistent with Nasdaq rules, to be at or above the market price of the Issuer’s
common shares (the “Equity Investment” and, with the Proposed Transaction, the “Proposed Transactions”). The Reporting
Person, as approved by the Issuer, may allow interested third parties to participate with him to fund a portion of the $5 million Equity
Investment on the same terms under the related agreement (the “Stock Purchase Agreement”).
In the Proposed Transactions, the Issuer would receive a 10% equity
position in Newco, an $8 million upfront cash payment and the $5 million Equity Investment, and Newco would assume certain liabilities
relating to the contributed assets, including assumption of certain expenses of the Issuer related to the development of those assets
between signing a definitive agreement and closing the Proposed Transaction. As a result, the Issuer would no longer have operational
or financial obligations for any of the programs contributed to Newco.
Any definitive agreement would contain customary closing conditions,
including the approval of the Proposed Transaction by the Issuer’s shareholders, and including Newco receiving minimum equity capital
commitments in order to fund the continued development of the CNS Programs.
The Reporting Person does not plan to make further filings unless and
until a definitive agreement is signed. The Issuer and Newco may fail to reach a definitive agreement for the Proposed Transaction, in
which event, neither the Proposed Transaction nor the Equity Investment would close.
| Item 5. | Interest in Securities of the Issuer. |
Item 5 of the Original Statement is hereby amended and restated in
its entirety to read as follows:
(a) The Reporting Person beneficially
owns an aggregate of 4,219,658 shares of Common Stock, representing (i) 2,047,698 shares of Common Stock held directly and (ii) an
additional 2,171,960 shares of Common Stock that underlie stock options that are currently exercisable or will be exercisable within 60
days of February 28, 2023. Share numbers are estimated based on the monthly vesting schedule of certain of the Reporting Person’s
stock options. The Reporting Person disclaims beneficial ownership of any shares of Common Stock owned by any other person.
(b) The information in Items
7 through 10 of the cover page is incorporated by reference into this Item 5(b).
(c) The Reporting Person has
not effected any transactions in the Common Stock during the past 60 days.
(d) - (e) Not applicable.
| Item 6. | Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. |
The description of the Stock Purchase Agreement in Item 4 of this Amendment
is incorporated herein by reference.
| Item 7. | Material to be Filed as Exhibits. |
Exhibit 1 Stock Purchase Agreement
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this Statement is true, complete and correct.
Date: April 3, 2023
PETER M. HECHT
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From Apr 2024 to May 2024
Cyclerion Therapeutics (NASDAQ:CYCN)
Historical Stock Chart
From May 2023 to May 2024